INVENTIVA news, videos and press releases
For more news please use our advanced search feature.
INVENTIVA - More news...
INVENTIVA - More news...
- Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
- Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
- Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
- Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
- Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
- Inventiva reports 2024 Third Quarter Financial Information¹
- Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
- Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
- Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
- Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
- Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
- Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024
- Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
- Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
- Inventiva announces the nomination of Andre Turenne as Director
- Inventiva reports its 2023 full-year results
- Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
- Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
- Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
- Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program
- Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH
- Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023
- Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates
- Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
- Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
- Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients
- Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023
- Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023
- Statement of total voting rights and shares forming the company’s share capital as of April 17, 2023
- Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F
